#Elanco #Australia #Melbourne #Neurizon #NUZ-001

Neurizon Therapeutics Welcomes Justine Conway as Board Observer

Neurizon Therapeutics Limited, a pioneering clinical-stage biotech company based in Melbourne, Australia, is making headlines with the appointment of Ms. Justine Conway as a Board Observer. This strategic move is aimed at strengthening the partnership with Elanco Animal Health, where Conway currently leads global business development efforts.

Strengthening Ties with Elanco

The relationship between Neurizon and Elanco is crucial for the advancement of innovative treatments for neurodegenerative diseases, particularly ALS. Conway’s inclusion as a Board Observer comes after Neurizon secured an exclusive global license agreement for Monepantel, a key component in their drug candidate NUZ-001. This collaboration forms a foundational basis for future clinical trials, regulatory approvals, and market entry.

As the global landscape of biotech continues to evolve, having industry leaders like Conway onboard is a strategic advantage for Neurizon. Her extensive experience in healthcare—spanning over two decades—positions her as a valuable asset to the company's board. Conway is set to enhance Neurizon's governance framework, providing insights that will be instrumental as the company progresses towards late-stage development of NUZ-001, and prepares for its entry into the HEALEY ALS Platform Trial.

A Wealth of Experience

Before joining Elanco in 2020, Conway held influential positions in investment banking, with significant tenures at Macquarie Bank and Bank of America Merrill Lynch. Her expertise encompasses various aspects of the pharmaceutical and biotech sectors, including executing crucial M&A transactions and capital raising activities. Conway's background in animal health and her strong global networks are anticipated to benefit Neurizon significantly.

Mr. Sergio Duchini, Non-Executive Chairman of Neurizon, expressed confidence in Conway's appointment, stating that her strategic insights will align with the company’s objectives and enhance their partnership with Elanco. He emphasized the invaluable impact of her experience as Neurizon is poised to advance toward regulatory submissions and commercial success in the near future.

Future Prospects

As Neurizon focuses on developing NUZ-001, a critical investigational product not yet approved for commercial use, the path forward is filled with promise. The company remains dedicated to addressing the urgent need for effective treatments for ALS and other neurodegenerative diseases. With initiatives like the HEALEY ALS Platform Trial on the horizon, Neurizon is at a pivotal moment in its journey toward transforming the lives of patients affected by these conditions.

In summary, Ms. Justine Conway's appointment as a Board Observer marks a significant step for Neurizon Therapeutics as it seeks to expand its influential partnerships, drive forward innovative treatments, and ultimately contribute to improving patient outcomes in neurology. The company invites stakeholders to join them on this exciting journey as they work diligently to bring effective therapeutic solutions to market.

About Neurizon Therapeutics

Neurizon Therapeutics Limited is committed to innovative research and development aimed at treating neurodegenerative diseases. With leading drug development strategies focused on ALS, Neurizon blends rigorous clinical programs with collaborative efforts to ensure their solutions reach those in need effectively. As they navigate the complexities of regulatory processes, the team remains optimistic about the future of both neurodegenerative treatments and improved patient care.

Note: NUZ-001 is currently an investigational product and is not yet available for commercial use around the globe.